Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Short Interest Update

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) saw a significant increase in short interest in December. As of December 31st, there was short interest totaling 424,089 shares, an increase of 34.6% from the December 15th total of 315,078 shares. Approximately 1.3% of the shares of the stock are short sold. Based on an average trading volume of 125,839 shares, the short-interest ratio is currently 3.4 days. Based on an average trading volume of 125,839 shares, the short-interest ratio is currently 3.4 days. Approximately 1.3% of the shares of the stock are short sold.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Jane Street Group LLC increased its stake in shares of Oramed Pharmaceuticals by 35.3% in the first quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company’s stock worth $144,000 after buying an additional 17,510 shares during the period. Wealth Enhancement Advisory Services LLC boosted its position in Oramed Pharmaceuticals by 36.2% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 18,799 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 5,000 shares during the period. BML Capital Management LLC grew its holdings in Oramed Pharmaceuticals by 2.1% in the 2nd quarter. BML Capital Management LLC now owns 3,083,253 shares of the biotechnology company’s stock worth $6,937,000 after acquiring an additional 62,505 shares during the last quarter. Finally, Bank of America Corp DE increased its position in shares of Oramed Pharmaceuticals by 4.4% in the third quarter. Bank of America Corp DE now owns 149,667 shares of the biotechnology company’s stock valued at $395,000 after acquiring an additional 6,261 shares during the period. 12.73% of the stock is owned by institutional investors.

Oramed Pharmaceuticals Trading Down 0.3%

Shares of Oramed Pharmaceuticals stock traded down $0.01 on Friday, hitting $3.68. 319,878 shares of the company traded hands, compared to its average volume of 253,934. The firm’s 50-day simple moving average is $2.90 and its 200 day simple moving average is $2.48. The company has a market cap of $146.46 million, a P/E ratio of 2.92 and a beta of 1.19. Oramed Pharmaceuticals has a 12-month low of $1.82 and a 12-month high of $3.71.

Oramed Pharmaceuticals Dividend Announcement

The firm also recently disclosed a dividend, which will be paid on Monday, January 26th. Stockholders of record on Friday, January 16th will be issued a $0.25 dividend. The ex-dividend date is Friday, January 16th.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Wall Street Zen raised shares of Oramed Pharmaceuticals to a “hold” rating in a report on Saturday, November 1st. Weiss Ratings reiterated a “hold (c)” rating on shares of Oramed Pharmaceuticals in a research report on Monday, December 29th. One research analyst has rated the stock with a Hold rating, According to MarketBeat, the company currently has an average rating of “Hold”.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.